Filing Details
- Accession Number:
- 0001136261-22-000249
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-02 16:29:45
- Reporting Period:
- 2022-06-01
- Accepted Time:
- 2022-06-02 16:29:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1017491 | Seelos Therapeutics Inc. | SEEL | Pharmaceutical Preparations (2834) | 870449967 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1376847 | J. Daniel O'connor | C/O Seelos Therapeutics, Inc. 300 Park Avenue, 2Nd Floor New York NY 10022 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-06-01 | 16,000 | $0.61 | 16,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $0.6054 per share to $0.6127 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.